Recently, a study demonstrated that CRISPR-Cas9-mediated deletion of SIRT1 promotes the release of exosomes (containing unique cargoes and hydrolases that degrade the extracellular matrix), impairs lysosomal function, and inhibits lysosomal acidification in MDA-MB-231 breast cancer cells [47]. Here, SIRT1 is linked to breast carcinoma.